RVAC Medicines Appoints Mohamed ElSayed, Ph.D., as Chief Technology Officer


Boston, MA – RVAC Medicines is pleased to announce that Mohamed ElSayed, Ph.D., has joined the company as Chief Technology Officer. Dr. ElSayed, a world-leading expert in complex drug delivery systems with more than 25 years of experience spanning academic, biotechnology, and pharmaceutical organizations, will lead the nucleic acid delivery technology efforts to bolster and advance the company’s pipeline. 

Dr. ElSayed joined RVAC Medicines from Eli Lilly & Company where he held positions of increasing responsibility in the Biotechnology Discovery Research Organization. He led the establishment of the oral peptides delivery platform, and the discovery and preclinical development of multiple oral biologics there. He is a recognized expert in the development of nucleic acid therapies. Earlier in his career, Dr. ElSayed was a tenured professor at the University of Michigan and served as an advisor for multiple biopharmaceutical companies. 

“We are excited to welcome Mohamed to the RVAC executive team. Delivery is a challenging yet potentially rewarding area for mRNA vaccine and therapeutics. Mohamed’s scientific expertise and strategic vision across multiple modalities and technology platforms will help RVAC build competitive advantages in the delivery space through internal research and external collaboration.” said Sean Fu, Ph.D., Chief Executive Officer of RVAC Medicines. 

“I’m inspired by RVAC Medicines’ ambitious goal of harnessing the power of nucleic acids to develop innovative vaccines and therapeutics for emerging markets; I look forward to working with the talented members of the RVAC team to vigorously pursue the discovery and development of new medicines for patients in need across the globe.” Dr. ElSayed said. 

Dr. ElSayed has a Ph.D. in Pharmaceutical Sciences from the University of Maryland. He is an inventor of 6 patents, co-author of 175 research publications, and recipient of 25 awards including Lilly Research Labs President's Scientific Recognition Award, National Science Foundation CAREER Award, and Coulter Foundation Translational Research Partnership in Biomedical Engineering Award. 

About RVAC Medicines
RVAC Medicines, incubated by CBC group, is an mRNA platform company headquartered in Singapore with R&D centers in Boston and Shanghai. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. Its leading asset, a COVID-19 vaccine, is quickly moving into clinical trials and well-positioned to serve emerging markets that are struggling with vaccine access. To achieve this mission, RVAC Medicines is establishing cutting-edge GMP manufacturing facilities that will advance its platform technologies through in-house R&D and external partnerships. The company is led by an experienced management team, supported by a world-renowned scientific advisory board. For more information, visit www.rvacmed.com, and follow the company on LinkedIn

About CBC Group 
CBC Group, Asia’s largest healthcare-dedicated investment firm, is committed to creating value and integrating global resources. Partnering with the world's top entrepreneurs and scientists, its unique investor-operator approach has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide. Founded in 2014, CBC has a leading team of investment, industry and portfolio management professionals headquartered in Singapore with offices in Shanghai, Beijing, Hong Kong and New York, and presences in Boston, San Diego, San Francisco, and Tokyo. CBC focuses on platform-building, buyout, credit and growth-focused opportunities across multiple core areas within the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services. For more information, please visit www.cbridgecap.com

Copyright RVAC Medicines All rights reserved 2023

Terms of use